Cutaneous lupus erythematosus (CLE) is a group of autoimmune diseases in which immune-mediated injury produces characteristic lesions of the skin and, sometimes, mucous membranes. It can occur independently or as part of systemic lupus erythematosus (SLE), a disease that may also affect joints, blood cells, kidneys, and other organs. The principal clinical categories are acute, subacute, and chronic cutaneous lupus. These categories differ in appearance, microscopic features, likelihood of permanent damage, and association with systemic disease.
CLE ranges from transient, non-scarring facial redness to persistent plaques that destroy hair follicles and leave permanent scars. Sensitivity to ultraviolet radiation is common, although the relationship between exposure and a flare is not always immediately apparent. Its importance extends beyond visible inflammation: altered pigmentation, scarring, hair loss, discomfort, and the social consequences of facial disease can substantially affect quality of life. Diagnosis depends on the pattern of lesions, their evolution, skin pathology, and a proportionate assessment for disease outside the skin.
Historical development, classification, and epidemiology
The word lupus, Latin for “wolf,” was historically applied to destructive skin conditions before modern distinctions between their causes existed. During the nineteenth century, dermatologists separated lupus erythematosus from other disorders carrying the same name, particularly lupus vulgaris, a form of cutaneous tuberculosis. Pierre Louis Alphée Cazenave described lupus erythematosus as a distinct entity in 1851. In 1872, Moriz Kaposi described forms associated with constitutional and internal manifestations, helping establish that lupus could extend beyond the skin.
Modern classification developed through correlations between clinical appearance, histopathology, laboratory findings, and systemic involvement. In 1979, Richard Sontheimer, John Thomas, and James Gilliam characterized subacute cutaneous lupus erythematosus as a recognizable subset. The subsequent Gilliam classification distinguished lupus-specific skin disease, which generally shows characteristic tissue changes, from lupus-nonspecific manifestations that can accompany SLE but occur in other conditions as well. Examples of the latter include some forms of vascular inflammation and diffuse non-scarring hair loss. This distinction remains useful because the presence of any skin abnormality in someone with SLE does not establish that the lesion itself is CLE.
The conventional division into acute, subacute, and chronic disease is practical rather than an absolute biological separation. A person may have more than one subtype simultaneously or develop different patterns over time. Discoid lupus is the most familiar chronic form, but chronic CLE also includes conditions involving deeper tissues or particular sites. The placement of lupus erythematosus tumidus varies between classification systems: some include it within chronic CLE, whereas others designate it as intermittent CLE because of its recurrent, non-scarring behavior and distinctive microscopic pattern.
The epidemiology of CLE is harder to measure than that of a single, consistently defined disease. Studies differ in whether they include patients with SLE, restrict enrollment to biopsy-confirmed cases, or use administrative diagnostic codes. Population-based studies have reported annual incidence in the range of several cases per 100,000 people, but estimates are not interchangeable across countries and study designs. Long disease duration also means that prevalence depends heavily on ascertainment and the age structure of the population.
CLE occurs at all ages and in all skin tones, although many patients first present during adulthood. Women are affected more frequently than men, but the sex imbalance is generally less pronounced than in SLE and differs by subtype. In several studied populations, discoid disease disproportionately affects people of African ancestry and is associated with substantial pigmentary and scarring damage. These observations reflect interacting biological, environmental, diagnostic, and healthcare factors; ancestry alone does not determine disease course. Childhood CLE is uncommon and deserves separate consideration because its relationship to systemic disease can differ from adult patterns.
Immune mechanisms and environmental triggers
CLE results from interactions among inherited susceptibility, environmental exposures, and dysregulated skin immunity. It is not an infection and is not transmitted by contact. Genetic associations overlap partly with those of systemic lupus, including variation in immune recognition, interferon signaling, and clearance of cellular debris. Rare inherited deficiencies of early complement components, particularly C1q, are strongly associated with lupus, illustrating the importance of removing dying cells without provoking inappropriate inflammation. Most CLE, however, is not explained by a single genetic defect.
Ultraviolet radiation is a major environmental trigger. Both UVA and UVB can contribute, through partly different effects on skin cells and immune responses. Irradiated keratinocytes—the predominant cells of the epidermis—undergo stress and sometimes programmed cell death. Intracellular material becomes more accessible to immune recognition, including nucleic acids and proteins such as Ro/SSA. In susceptible skin, inadequate disposal of this material and exaggerated sensing of nucleic acids can turn an ordinary response to injury into sustained autoimmunity. Lesions may develop days or weeks after exposure, making the provoking event difficult to recognize.
Type I interferons are central to this process. These signaling proteins normally help coordinate antiviral defense, but persistent activation can promote autoimmune inflammation. Keratinocyte-derived interferon-kappa and interferon produced by immune cells contribute to an interferon-rich cutaneous environment. Plasmacytoid dendritic cells can respond to nucleic-acid-containing immune complexes and amplify this signaling. Other inflammatory pathways, including interferon-gamma and additional cytokines, interact with the type I interferon response rather than acting as wholly separate systems.
Activated T cells accumulate around vessels, skin appendages, and the junction between epidermis and dermis. Cytotoxic cells can injure basal keratinocytes, producing the microscopic pattern called interface dermatitis. In discoid lesions, inflammation may extend around hair follicles and damage the follicular stem-cell region. Once that regenerative compartment is destroyed, hair loss becomes permanent. Fibroblast activation and tissue remodeling then contribute to fibrosis and scarring. By contrast, inflammatory patterns that spare these structures can resolve without permanent architectural damage.
Other exposures modify risk or disease expression. Cigarette smoking is associated with CLE and, in some studies, with greater severity or reduced response to antimalarial treatment, although disease severity and other confounders complicate interpretation. Certain medicines can provoke subacute CLE, and cold exposure is relevant to chilblain lupus. Mechanical injury may occasionally localize lesions through the Koebner phenomenon, in which disease appears at a previously injured site. These triggers do not act uniformly: marked photosensitivity in one patient does not imply that every lesion in another is sunlight-induced, and the absence of a remembered trigger does not exclude CLE.
Acute and subacute cutaneous lupus
Acute cutaneous lupus erythematosus (ACLE) is closely associated with systemic lupus and often appears during periods of increased systemic disease activity. Its classic localized form is the malar or “butterfly” eruption: relatively fixed redness, sometimes with swelling, across the cheeks and nasal bridge. The nasolabial folds are often spared, although this is not an absolute diagnostic rule. The eruption usually persists longer than ordinary flushing and may follow sun exposure. Unlike discoid lupus, it generally heals without scarring, although temporary pigmentary change can remain.
Generalized ACLE produces a widespread inflammatory eruption, often on sun-exposed skin. Lesions may be macular, papular, or confluent, and the hands can show a distribution that relatively spares the skin directly over the knuckles. This pattern can help distinguish lupus from dermatomyositis, but no single distribution is definitive. Rare, severe presentations involve extensive epidermal injury and can resemble serious drug reactions. Acute cutaneous findings therefore require interpretation alongside systemic symptoms, exposure history, and tissue findings rather than identification from facial redness alone.
Subacute cutaneous lupus erythematosus (SCLE) typically produces photosensitive lesions on the upper chest, back, shoulders, and outer arms. Two principal patterns occur. Annular lesions form rings or polycyclic shapes with raised, scaly borders and relative central clearing. Papulosquamous lesions are more confluent and can resemble psoriasis or an eczematous eruption. Both patterns may occur in the same person. The central face is often less prominently affected than in ACLE, but distribution varies. SCLE generally resolves without true scarring, although persistent light or dark discoloration may be conspicuous.
SCLE has a strong association with antibodies to Ro/SSA, which are present in a large majority of patients in many clinical series. These antibodies support classification in the appropriate clinical setting but are neither exclusive to SCLE nor sufficient to diagnose it. Some patients meet classification criteria for SLE because of accompanying serological, joint, or blood abnormalities. Severe renal or neurological involvement is less characteristic of SCLE cohorts than of many unselected SLE cohorts, but it remains possible; the skin subtype does not replace assessment of other organs.
Drug-induced SCLE is clinically important because it may closely resemble disease arising without a medication trigger. Reported associations include thiazide diuretics, terbinafine, proton-pump inhibitors such as omeprazole, and several cardiovascular, immune-modifying, and anticancer medicines. Latency ranges from weeks to much longer periods, so a recently started drug is not the only relevant exposure. Improvement after withdrawal can take weeks or months, while autoantibodies may persist. Medication association is assessed from chronology, known drug effects, competing explanations, and subsequent course; the presence of SCLE during treatment does not by itself establish causation.
Discoid lupus and other chronic cutaneous forms
Discoid lupus erythematosus (DLE) produces persistent, well-demarcated plaques with adherent scale, follicular plugging, and progressive changes in pigmentation and skin structure. Early lesions may appear as red or violaceous patches with a rough surface. As they evolve, the center can become pale, thin, and scarred while the edge remains inflamed and darker. On the scalp, destruction of follicles causes scarring hair loss. Lost follicular openings help distinguish established scarring alopecia from reversible shedding.
Localized DLE principally affects the head and neck, especially the scalp, ears, and face. Generalized DLE extends beyond these regions and is associated with a greater likelihood of systemic involvement than localized disease. Lesions can also affect mucosal surfaces, including the lips and oral cavity. Chronic lip lesions require careful distinction from other inflammatory and neoplastic conditions. DLE plaques may be conspicuous in darker skin because both hyperpigmentation and depigmentation can remain after active inflammation subsides; visible damage is not necessarily evidence of continuing immune activity.
Hypertrophic, or verrucous, lupus is an uncommon chronic variant characterized by thick, warty, hyperkeratotic lesions. It can resemble hypertrophic lichen planus or squamous cell carcinoma. Lupus panniculitis, also called lupus profundus in some usage, primarily affects subcutaneous fat and produces deep, firm nodules or plaques. The overlying skin may be normal or show discoid changes. Inflammation and loss of fat can leave permanent depressions, particularly on the face, upper arms, or trunk. Its tissue findings must sometimes be distinguished from subcutaneous panniculitis-like lymphoma, a separate disease with important differences in management and prognosis.
Chilblain lupus typically causes persistent red-purple lesions on fingers, toes, ears, or other acral sites after cold exposure. Lesions can be painful, fissured, or ulcerated and may resemble ordinary chilblains. Persistence, other lupus features, serology, and biopsy help establish the distinction. Rare familial forms are associated with abnormalities in nucleic-acid metabolism, including variants in the TREX1 gene. These inherited disorders have helped connect excessive interferon signaling with lupus-like skin inflammation, although most chilblain lupus is not explained by these rare variants.
Lupus erythematosus tumidus presents with smooth, swollen, urticaria-like plaques, often on sun-exposed areas. Scale, follicular plugging, and epidermal damage are usually absent, and lesions generally heal without scars. Microscopy commonly shows superficial and deep lymphocytic inflammation with abundant dermal mucin and little or no interface injury. These features distinguish it from classic DLE and explain its variable placement in classification schemes. Across chronic variants, the word chronic describes the disease pattern, not an assurance that every lesion remains continuously active or that all forms cause the same degree of permanent damage.
Clinical diagnosis, skin pathology, and differential diagnosis
The diagnosis of CLE begins with lesion morphology, distribution, duration, symptoms, and evolution. Examination distinguishes active redness, swelling, and scale from established scars, atrophy, and pigment alteration. The scalp, ears, lips, oral mucosa, and other potentially involved sites can provide information not apparent from the most visible eruption. A detailed medical history establishes relationships to sunlight, cold, medications, smoking, previous episodes, and possible systemic features. Photographs can help document changes because individual lesions may fluctuate between assessments.
A skin biopsy is often useful, especially when the appearance is atypical, treatment response is unexpected, or a scarring disorder needs clarification. Typical epidermal forms show interface dermatitis with basal-cell injury, apoptotic keratinocytes, and lymphocytic inflammation. DLE may additionally show follicular plugging, basement-membrane thickening, and inflammation around follicles and other appendages. Dermal mucin—material rich in glycosaminoglycans—can support the diagnosis but is not unique to lupus. The depth and site of sampling matter: a superficial specimen may miss lupus panniculitis, while an old scar may reveal little about the original inflammatory process.
Direct immunofluorescence can demonstrate immunoglobulin and complement deposits along the dermoepidermal junction, historically termed the lupus band. Its interpretation depends on whether the sampled skin is lesional or unaffected and whether it is sun-exposed. Similar deposits can occur in other circumstances, and a negative result does not exclude CLE. Consequently, immunofluorescence is an adjunct rather than an independent diagnostic verdict. Clinical and routine histological correlation generally carries greater weight than an isolated positive “lupus band.”
Laboratory evaluation addresses both diagnostic context and possible systemic disease. An antinuclear antibody test may be positive, especially in ACLE and SCLE, but can be negative in localized DLE. Anti-Ro/SSA antibodies are particularly relevant to SCLE; anti-double-stranded DNA and anti-Sm antibodies are more closely associated with SLE. A complete blood count, measures of renal function, and urine testing can identify abnormalities not explained by skin disease alone. Complement levels and additional testing are selected according to the broader clinical picture. No single blood result establishes the presence, severity, or absence of all forms of CLE.
The differential diagnosis varies with the subtype. Facial ACLE may resemble rosacea, seborrhoeic dermatitis, phototoxic reactions, or dermatomyositis. SCLE overlaps visually with psoriasis, eczema, tinea corporis, and other photosensitive eruptions. DLE can resemble lichen planus and other inflammatory causes of scarring alopecia. Tumid lupus overlaps with polymorphic light eruption and other lymphocytic dermal disorders. These alternatives explain why neither a butterfly-shaped rash nor photosensitivity alone is specific for lupus, and why pathology must be interpreted in the context of the particular lesion sampled.
Relationship to systemic lupus and pregnancy
Cutaneous and systemic lupus overlap, but they are not interchangeable diagnoses. Skin disease may precede SLE, appear with it, or remain confined to the skin for many years. ACLE has the strongest association with established systemic lupus. SCLE frequently accompanies autoantibodies and sometimes mild extracutaneous disease. Localized DLE has a lower association, although systemic disease can still occur. Multiple cutaneous patterns may coexist, and the relationship between skin activity and internal-organ activity differs between individuals and subtypes.
Reported progression from initially skin-limited CLE to SLE varies considerably across studies. Differences reflect follow-up duration, referral setting, age, subtype, and the criteria used to define SLE. Some cohorts identify progression through combinations of skin, serological, joint, or blood findings without major organ disease; others include patients who later develop substantial systemic involvement. Therefore, a single percentage cannot accurately describe every person with CLE. Findings repeatedly associated with greater concern for systemic disease include broader autoantibody profiles, blood-count abnormalities, and pre-existing extracutaneous manifestations.
Clinical assessment distinguishes nonspecific symptoms from evidence of organ inflammation. Fatigue and joint pain can occur in many conditions and do not independently establish SLE. By contrast, inflammatory arthritis, certain blood-cell abnormalities, or persistent urinary abnormalities can materially change the assessment. Lupus nephritis may initially be detected through protein or blood in the urine rather than symptoms. This is why evaluation of possible systemic involvement is not limited to asking whether the patient feels unwell. Classification criteria support research consistency but are not a substitute for clinical diagnosis.
A separate issue concerns anti-Ro/SSA and anti-La/SSB antibodies during pregnancy. These maternal antibodies can cross the placenta and are associated with neonatal lupus, even when the mother has limited or no symptoms. Neonatal cutaneous lupus commonly produces annular lesions and generally resolves as transferred maternal antibodies disappear. Congenital heart block is a different, potentially permanent manifestation. Among anti-Ro-positive pregnancies without a previously affected child, its risk is approximately 1–2%; recurrence risk is substantially higher after an affected pregnancy. These risks concern the maternal antibody profile, not the appearance or extent of maternal skin lesions alone.
CLE also needs distinction from skin manifestations that occur in SLE but are not lupus-specific lesions. Vascular lesions, some forms of urticaria, diffuse hair shedding, and abnormalities related to antiphospholipid antibodies can have different mechanisms and implications. Similarly, a person with lupus can independently develop contact dermatitis, infection, or another common skin disorder. Accurate attribution prevents unrelated findings from being treated as evidence that systemic lupus has become more active.
Treatment approaches and their evidence base
Treatment is directed at suppressing active inflammation, limiting new lesions, and preventing irreversible damage. The choice of therapy reflects subtype, distribution, scarring risk, associated systemic disease, reproductive considerations, and previous response. Measures that reduce ultraviolet exposure are a standard component of clinical management because photoprovocation studies and clinical experience support the role of ultraviolet radiation in many forms of CLE. Broad-spectrum sunscreens, protective clothing, and modification of exposure are used together rather than being considered interchangeable. Drug-induced SCLE also requires assessment of the suspected medication and the consequences of changing it.
Localized inflammation is commonly treated with topical corticosteroids. Their potency and duration are balanced against local adverse effects, including skin thinning and visible small vessels, particularly on the face. Intralesional corticosteroids are used for selected resistant plaques. Topical calcineurin inhibitors, such as tacrolimus, provide a steroid-sparing option, especially at sites vulnerable to atrophy. These treatments act on inflammatory activity; they do not reconstruct follicles or normal skin architecture already lost to scarring.
Antimalarial medicines are the principal systemic treatment for many patients with CLE. Hydroxychloroquine is generally preferred because of its balance of experience, effectiveness, and safety. Its effects include modulation of endosomal signaling and innate immune activation rather than direct suppression of a single antibody. Clinical improvement often takes several weeks to months. Retinal toxicity is an important cumulative risk, influenced by daily exposure, duration, renal function, and other factors; prescribing and ophthalmic surveillance therefore form part of treatment safety. Chloroquine or quinacrine may be used in selected settings, although availability and adverse-effect profiles differ.
For disease that remains active despite initial therapy, specialist practice includes agents such as methotrexate, mycophenolate, or selected other immunomodulators. Dapsone has a particular role in some bullous or neutrophil-rich lupus presentations, while systemic retinoids can be useful for selected hyperkeratotic disease. Short courses of systemic corticosteroids may rapidly suppress severe inflammation, but long-term exposure is limited by complications such as infection, metabolic effects, and osteoporosis. Thalidomide can be effective in refractory CLE, yet its use is severely constrained by teratogenicity, peripheral neuropathy, thrombosis risk, and frequent relapse after discontinuation.
The strength of evidence is uneven across treatments. Many conventional therapies are supported by clinical experience, observational studies, and relatively small trials rather than large CLE-specific randomized controlled trials. Biologic agents approved for SLE, including belimumab and anifrolumab, have demonstrated benefits in mucocutaneous outcomes in SLE studies, but those findings do not automatically establish the same indication for every form of skin-limited lupus. Regulatory approval varies by jurisdiction and disease indication. Treatment response is also harder to judge when irreversible discoloration or scars are mistaken for persistent active inflammation.
Disease course, lasting effects, and research priorities
CLE often follows a relapsing course, with episodes of activity separated by partial or complete improvement. Its long-term impact depends strongly on subtype and the structures injured. ACLE and SCLE generally do not cause true scarring, whereas DLE and lupus panniculitis can leave permanent changes. Even after inflammation has stopped, pigment alteration may persist for months or longer. Distinguishing ongoing disease from residual damage is therefore fundamental to describing prognosis, interpreting photographs, and assessing whether treatment is controlling the inflammatory process.
The consequences of visible disease are not captured by lesion counts alone. Facial plaques, scalp scarring, and pigment changes can affect social participation, employment, and emotional well-being. Itching and pain may add burden even when the involved area is small. Studies using dermatology-specific and lupus-related patient-reported outcomes document effects on daily life that may not parallel a clinician’s estimate of skin severity. Depression and anxiety symptoms can coexist, but psychological distress is neither an explanation for the skin lesions nor evidence that their inflammatory basis is uncertain.
The Cutaneous Lupus Erythematosus Disease Area and Severity Index, usually abbreviated CLASI, was developed to make assessment more reproducible. It separates activity—such as erythema and scale—from damage, including scarring and dyspigmentation. This separation allows trials to detect suppression of inflammation without requiring old scars to disappear. Measures such as a 50% reduction in the activity score are used in research, although their interpretation depends on baseline severity and study design. Assessment across different skin tones remains important because erythema may be less visually apparent in heavily pigmented skin, while pigmentary consequences may be especially prominent.
Chronic scarred DLE lesions can rarely develop squamous cell carcinoma, a form of skin cancer. Reported cases often involve longstanding lesions, including those on the lips or other sun-exposed sites. The absolute risk is difficult to quantify from case series because unusual or severe cases are more likely to be published. A changing ulcerated, thickened, or growing area is diagnostically different from a stable old scar and may require renewed tissue assessment. The existence of this complication does not mean that most discoid lesions become malignant.
Research increasingly targets specific immune circuits rather than broadly suppressing immunity. Investigational approaches have included antibodies directed at BDCA2, a receptor on plasmacytoid dendritic cells, and therapies targeting interferon-associated signaling. Molecular studies examine whether apparently similar lesions contain distinct inflammatory programs that could predict response. Candidate biomarkers include tissue interferon signatures and immune-cell patterns, but these have not replaced clinical assessment in routine care. Persistent challenges include recruiting adequately sized CLE-specific trials, distinguishing drug effects from seasonal variation, representing diverse skin tones and subtypes, and measuring outcomes that reflect both biological activity and the lived burden of permanent damage.